454 results on '"Westervelt, Peter"'
Search Results
2. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
3. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
4. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
5. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
6. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant
7. Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
8. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice
9. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802
10. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
11. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
12. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
13. Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease
14. Analysis of the Proteomes of Primary, De Novo Acute Myeloid Leukemia Cells from Adults
15. Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression
16. A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
17. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
18. Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission
19. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
20. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
21. Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
22. Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
23. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
24. Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
25. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
26. Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
27. The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients
28. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression
29. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
30. Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance
31. Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone
32. Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product
33. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
34. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
35. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML
36. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML
37. Seed Versus Soil: The Importance of the Target Cell for Transgenic Models of Human Leukemias
38. Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy)
39. Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant
40. Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation
41. Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant
42. Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1
43. Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning
44. Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
45. A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)
46. The Use of CD34+-Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation
47. ABO Mismatch Status Does Not Influence the Clinical Outcomes in Haploidentical Hematopoeitic Cell Transplantation
48. Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS
49. DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression
50. Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.